Showing results (41-50 of 73) with videos related to
Sort By:
Pageof 8
Rheumatology (Oxford, England)|May 12, 2012
T cells in systemic sclerosis: a reappraisalSteven O'Reilly, Thomas Hügle, Jacob M van LaarPharmacology & Therapeutics|August 7, 2018
Targeting TLRs and the inflammasome in systemic sclerosisJohn Henderson, Swati Bhattacharyya, John Varga, et al.Journal of Cellular and Molecular Medicine|November 3, 2020
Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesisJohn Henderson, Laura Duffy, Richard Stratton, et al.Epigenetics|September 23, 2020
microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosisJohn Henderson, Sarah Wilkinson, Stefan Przyborski, et al.Clinical & Translational Immunology|December 16, 2014
Interleukin-6: a new therapeutic target in systemic sclerosis?Steven O'Reilly, Rachel Cant, Marzena Ciechomska, et al.The Journal of Biological Chemistry|February 20, 2014
Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin proteinSteven O'Reilly, Marzena Ciechomska, Rachel Cant, et al.Immunology Letters|August 29, 2017
Innate lymphoid cells and fibrotic regulationSteven Horsburgh, Stephen Todryk, Andreas Ramming, et al.Cytokine & Growth Factor Reviews|May 8, 2012
Interleukin-6, its role in fibrosing conditionsSteven O'Reilly, Marzena Ciechomska, Rachel Cant, et al.Plos One|March 21, 2012
Differentiation potential of CD14+ monocytes into myofibroblasts in patients with systemic sclerosisNadine Binai, Steven O'Reilly, Bridget Griffiths, et al.Expert Reviews in Molecular Medicine|August 30, 2013
Role of toll-like receptors in systemic sclerosisMarzena Ciechomska, Rachel Cant, James Finnigan, et al.Pageof 8